drugset / Trial / NCT00754065

To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)

NCT00754065

Phase 3 Completed 409 enrolled Bayer
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of the study is to compare the oral contraceptive (OC) SH T00658ID over Ortho Tri-Cyclen Lo administered for 13 cycles to healthy female volunteers between 18 and 50 years of age who request oral contraceptive protection. Subjects on a levonorgestrel (LNG), norgestimate (NGM), norethindrone or norethindrone acetate containing oral contraceptive in a 21-day regimen suffering from hormone withdrawal-associated symptoms such as pelvic pain or headache or both, and willing to continue OC use but to switch to SH T00658ID or Ortho Tri-Cyclen Lo.

Timeline

Start
2008-09-08
Primary completion
2011-05-10
Completion
2011-05-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Dienogest Small molecule 3 mg Oral
Comparator Norgestimate Small molecule 0.215 mg Oral
Subject estradiol valerate Unknown 2 mg Oral
Comparator ethinyl estradiol Small molecule 0.025 mg Oral

Indications

No indication recorded.